Table 3.
Survey of cannabis-based product (CBP) users (n = 55) compared to non-users (n = 133): demographics, MS-specific data, previous and current disease modifying treatments (DMTs) and symptomatic treatments.
| CBP usersn (%) | CBP non-users n (%) | Un-adjustedp-value | |
|---|---|---|---|
| Gender (n = 187) | 0.86 | ||
| Male | 14 (25) | 37 (28) | |
| Female | 41 (75) | 95 (72) | |
| Age (years) (n = 188) | |||
| 18–25 | 1 (2) | 3 (2) | 0.89 |
| 25–35 | 15 (27) | 25 (19) | |
| 35–45 | 11 (20) | 29 (22) | |
| 45–55 | 13 (24) | 38 (29) | |
| 55–65 | 12 (22) | 30 (23) | |
| 66+ | 3 (5) | 8 (6) | |
| Employment status (n = 173) | 0.006 | ||
| Full-time | 13 (25) | 61 (51) | |
| Part-time | 7 (13) | 15 (12) | |
| At home caregiver | 5 (9) | 5 (4) | |
| Disability/unemployed | 28 (53) | 39 (32) | |
| Disease course (n = 188) | 0.74 | ||
| Relapsing remitting | 34 (62) | 87 (65) | |
| Clinically isolated syndrome | 0 (0) | 3 (2) | |
| Primary progressive | 8 (15) | 12 (9) | |
| Secondary progressive | 3 (5) | 8 (6) | |
| Unsure | 10 (18) | 23 (17) | |
| Disease duration (years) (n = 182) | 0.84 | ||
| <1 | 6 (11) | 10 (8) | |
| 1–5 | 9 (17) | 26 (20) | |
| 5–10 | 11 (21) | 25 (19) | |
| >10 | 27 (51) | 68 (53) | |
| Disability (NARCOMS) (n = 183) | 0.034 | ||
| 0–2 | 26 (49) | 89 (68) | |
| 3–5 | 24 (45) | 34 (26) | |
| 6–8 | 3 (6) | 7 (5) | |
| No. previous DMTs (n = 188) | 0.001 | ||
| 0–1 | 25 (45) | 98 (74) | |
| 2–3 | 26 (47) | 31 (23) | |
| 4–6 | 4 (7) | 4 (3) | |
| Current DMT (n = 188) | 0.33 | ||
| None | 33 (60) | 80 (60) | |
| 1st line | 9 (16) | 32 (24) | |
| 2nd Line | 13 (24) | 21 (16) | |
| No. symptomatic treatments (n = 188) | 0.002 | ||
| 0–1 | 31 (56) | 108 (81) | |
| 2–3 | 14 (25) | 15 (11) | |
| 4+ | 10 (18) | 10 (8) |